Two Sigma Investments LP raised its holdings in shares of Paysign, Inc. (NASDAQ:PAYS – Free Report) by 98.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 181,775 shares of the company’s stock after purchasing an additional 90,346 shares during the quarter. Two Sigma Investments LP owned 0.34% of Paysign worth $549,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. PDT Partners LLC acquired a new position in shares of Paysign during the fourth quarter valued at about $39,000. Wells Fargo & Company MN raised its holdings in shares of Paysign by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 15,385 shares of the company’s stock worth $46,000 after acquiring an additional 5,243 shares during the last quarter. SG Americas Securities LLC lifted its position in Paysign by 33.5% in the 4th quarter. SG Americas Securities LLC now owns 15,508 shares of the company’s stock valued at $47,000 after acquiring an additional 3,895 shares in the last quarter. Virtu Financial LLC acquired a new position in Paysign during the 4th quarter valued at about $78,000. Finally, Occudo Quantitative Strategies LP boosted its stake in Paysign by 56.5% during the 4th quarter. Occudo Quantitative Strategies LP now owns 28,429 shares of the company’s stock valued at $86,000 after purchasing an additional 10,268 shares during the last quarter. Institutional investors and hedge funds own 25.89% of the company’s stock.
Paysign Stock Up 4.7%
Shares of NASDAQ PAYS opened at $4.93 on Monday. The company has a market capitalization of $267.29 million, a PE ratio of 32.87 and a beta of 0.60. The stock’s 50 day moving average price is $2.88 and its 200-day moving average price is $2.85. Paysign, Inc. has a twelve month low of $1.80 and a twelve month high of $5.59.
Wall Street Analyst Weigh In
Several analysts have recently commented on PAYS shares. DA Davidson increased their price objective on Paysign from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Wednesday, May 14th. Barrington Research reiterated an “outperform” rating and set a $7.00 price target on shares of Paysign in a report on Wednesday, March 26th. Lake Street Capital increased their price target on Paysign from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Friday, May 9th. Finally, LADENBURG THALM/SH SH lifted their price objective on shares of Paysign from $7.25 to $8.25 and gave the stock a “buy” rating in a report on Friday, May 9th.
Check Out Our Latest Research Report on PAYS
Insider Buying and Selling at Paysign
In other Paysign news, Director Daniel R. Henry bought 19,800 shares of the business’s stock in a transaction on Wednesday, May 14th. The stock was purchased at an average price of $3.42 per share, for a total transaction of $67,716.00. Following the completion of the transaction, the director now directly owns 99,800 shares of the company’s stock, valued at $341,316. This trade represents a 24.75% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Mark Newcomer sold 168,000 shares of the stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $4.51, for a total transaction of $757,680.00. Following the transaction, the chief executive officer now owns 8,768,886 shares of the company’s stock, valued at $39,547,675.86. This represents a 1.88% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 22.40% of the company’s stock.
Paysign Profile
Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.
Featured Stories
- Five stocks we like better than Paysign
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Five Below Pops on Strong Earnings, But Rally May Stall
- What is the Nasdaq? Complete Overview with History
- Intel’s Dual Gamble: AI Innovation Now, Foundry Fortunes Later?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- X: 1 Reason to Bet on U.S. Steel, and 1 Reason to Hold Back
Receive News & Ratings for Paysign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paysign and related companies with MarketBeat.com's FREE daily email newsletter.